GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02560376

UnknownPhase EARLY_1

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

Lead sponsor

Peking Union Medical College Hospital

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

100

estimated

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02560376

Org study IDPUMCHNM12

Secondary IDZIAEB000073

Timeline

Milestones

Study first posted2015-09-25estimated

Last update posted2015-09-25estimated

Study start2014-02 (month precision)

Primary completion2016-12estimated (month precision)

Study completion2016-12estimated (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age6 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients with hypoglycaemia in the presence of neuroglycopenic symptoms and documented Whipple's triad.

•Biochemically proven endogenous hyperinsulinemic hypoglycaemia (plasma glucose concentration <3.0 mM, insulin >3 µU/ml, and C-peptide >0.6 ng/ml).

•Conventional imaging within 1 month

•Signed written consent

•Age above 6 years (congenital hyperinsulinemic with the symptoms onset in school age is also the subject of this study)

Exclusion criteria

•Pregnancy

•Breastfeeding

•Renal function: serum creatinine > 3.0 mg/dl

•Known allergy against exendin-4

•Any medical condition that, in the opinion of the investigator, may significantly interfere with study compliance.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other (unclassified)

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Adverse events collection

Time frame:1 week

Treatment-emergent AEs (any)

event count, event

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis

Time frame:1 year

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Glucagon-like peptide-1 receptor PET/CT with (68)Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.
European journal of nuclear medicine and molecular imaging2025 Oct (month)PMID40310561doi:10.1007/s00259-025-07298-9via pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.